POMDOCTOR LIMITED Announces Receipt of Nasdaq Notice

POMDOCTOR LIMITED (NASDAQ: POM) received a Nasdaq Deficiency Letter dated Jan 29, 2026, reporting the ADS closing bid price was below the required $1.00 minimum for 33 consecutive business days.

Rhea-AI Summary

POMDOCTOR LIMITED (NASDAQ: POM) received a Nasdaq Deficiency Letter dated Jan 29, 2026, reporting the ADS closing bid price was below the required $1.00 minimum for 33 consecutive business days. The letter currently does not affect listing or trading.

The company has a 180-calendar-day compliance period ending July 28, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days; Nasdaq may grant additional time at its discretion.

Positive

• ADSs remain listed and tradable while the Deficiency Letter has no current effect
• Company granted a 180-calendar-day compliance period through July 28, 2026
• Regain condition clearly defined: $1.00 closing bid for 10 consecutive business days

Negative

• Closing bid below $1.00 for 33 consecutive business days
• Company faces potential Nasdaq compliance risk if not regained by July 28, 2026
• Possible further review or delisting proceedings if Nasdaq does not grant additional time

Argus Feb 2 session

+5.15% close to close Open Argus

Details

News Market Reaction – POM

On Feb 2, the day this news came out, POM closed 5.15% above the previous close.

Data tracked by StockTitan Argus for the Feb 2 session.

Market Context

On Feb 2, the day this news came out, the stock closed 5.2% above the previous close. A strong posit...

Analysis

On Feb 2, the day this news came out, the stock closed 5.2% above the previous close. A strong positive reaction aligns with a pattern where most prior corporate milestones, such as the IPO and over-allotment exercise, saw price moves track the generally positive tone. However, today’s Nasdaq minimum-bid-price deficiency notice highlights that the stock traded at just US$0.2311, far below the US$1.00 threshold and its prior US$6.43 high. Investors would need to weigh any upside move against ongoing listing risk and the company’s recent history of net losses.

Key Figures

Non-compliance days: 33 consecutive business days Nasdaq minimum bid price: US$1.00 per share Initial compliance period: 180 calendar days +5 more

Non-compliance days

33 consecutive business days

Closing bid below US$1.00 requirement

Nasdaq minimum bid price

US$1.00 per share

Nasdaq Listing Rule 5450(a)(1)

Initial compliance period

180 calendar days

Compliance period ending July 28, 2026

Compliance deadline

July 28, 2026

End of initial Nasdaq bid price compliance period

Required bid-price streak

10 consecutive business days

Minimum period at or above US$1.00 to regain compliance

Current price

US$0.2311

Before announcement; at 52-week low and below US$1.00

52-week high

US$6.43

Price is substantially below prior 12-month peak

Market cap

US$26,365,837

Equity value prior to Nasdaq notice

Historical Context

4 past events · Latest: Jan 16

4 events

1. Jan 16

   Strategic partnerships

   24h Move

   -1.7%

   Strengthened collaborations with domestic pharma firms for internet hospital growth.

2. Dec 03

   Earnings update

   24h Move

   +5.4%

   First-half 2025 results with revenue and gross profit growth despite net loss.

3. Oct 10

   Overallotment exercise

   24h Move

   +1.1%

   Full exercise of underwriter’s option to buy additional ADSs at IPO price.

4. Oct 09

   IPO completion

   24h Move

   +18.4%

   Closing of initial public offering of ADSs on Nasdaq Global Market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

american depositary shares, nasdaq listing rule 5450(a)(1), minimum bid price, compliance period

4 terms

american depositary shares financial

"the closing bid price of the Company's American depositary shares (the "ADSs")"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

nasdaq listing rule 5450(a)(1) regulatory

"minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1)"

Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

minimum bid price regulatory

"was below the minimum bid price of US$1.00 per share requirement"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

compliance period regulatory

"provided with a compliance period of 180 calendar days, or until July 28, 2026"

A compliance period is a defined stretch of time during which a company must meet specific legal, regulatory, or contractual rules and reporting requirements. Think of it like a scheduled inspection window or a homework deadline: failing to satisfy the rules within that window can trigger fines, restrictions, or extra oversight, so investors watch compliance periods as signals of near-term legal risk, potential costs, and impacts on a company’s operations or cash flow.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GUANGZHOU, China, Feb. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it has received a written notification (the "Deficiency Letter") from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated January 29, 2026, indicating that for the last 33 consecutive business days, the closing bid price of the Company's American depositary shares (the "ADSs") was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Deficiency Letter has no current effect on the listing or trading of the Company's ADSs on Nasdaq.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until July 28, 2026 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price of the Company's ADSs is at least US$1.00 for a minimum of ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance by July 28, 2026, subject to the determination by the staff of Nasdaq, the Company may be eligible for additional time.

The Deficiency Letter will have no effect on the Company's business operations, and the Company will take all reasonable measures to regain compliance.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-receipt-of-nasdaq-notice-302674985.html

SOURCE POMDOCTOR LIMITED

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did POM announce about the Nasdaq Deficiency Letter on February 2, 2026?

POM announced it received a Nasdaq Deficiency Letter after 33 consecutive business days below $1.00. According to the company, the letter currently does not affect listing or trading and identifies the minimum bid price deficiency.

How long does POM have to regain Nasdaq compliance (symbol POM)?

POM has a 180-calendar-day compliance period ending July 28, 2026 to regain the minimum bid price. According to the company, Nasdaq may grant additional time at its discretion if criteria are not met.

What is the requirement for POM to regain Nasdaq compliance?

To regain compliance POM must have the ADS closing bid at least $1.00 for 10 consecutive business days. According to the company, Nasdaq will confirm compliance in writing once this condition is met.

Does the Nasdaq Deficiency Letter affect POM’s trading or operations now?

The Deficiency Letter has no current effect on POM’s listing or trading on Nasdaq. According to the company, the letter does not impact its business operations and it will pursue measures to regain compliance.

What happens if POM does not regain compliance by July 28, 2026?

If POM does not regain compliance by July 28, 2026, Nasdaq may determine eligibility for additional time or begin delisting procedures. According to the company, any additional time is subject to Nasdaq staff determination.